Responses to O-FC by pretreatment characteristics and number of treatment courses received
| Characteristic . | n* . | CR rate, % . | OR rate, % . |
|---|---|---|---|
| All patients | 61 | 41 | 75 |
| Sex | |||
| Male | 43 | 35 | 70 |
| Female | 18 | 56 | 89 |
| Age, y | |||
| < 65 | 50 | 44 | 76 |
| ≥ 65 | 11 | 27 | 73 |
| ECOG performance status | |||
| 0 | 34 | 47 | 82 |
| 1-2 | 27 | 33 | 67 |
| Palpable lymph nodes | |||
| ≤ 5 cm | 51 | 39 | 78 |
| > 5 cm | 10 | 50 | 60 |
| Rai stage | |||
| 0-II | 33 | 36 | 73 |
| III-IV | 28 | 46 | 79 |
| Binet stage | |||
| A | 8 | 38 | 75 |
| B | 33 | 42 | 79 |
| C | 20 | 40 | 70 |
| β-2M† | |||
| < 4 mg/L | 32 | 53 | 84 |
| ≥ 4 mg/L | 28 | 29 | 68 |
| Lactate dehydrogenase† | |||
| < 228 IU/L | 30 | 40 | 77 |
| ≥ 228 IU/L | 31 | 42 | 74 |
| Thymidine kinase† | |||
| < 29 IU/L | 29 | 45 | 76 |
| ≥ 29 IU/L | 30 | 40 | 80 |
| ALC† | |||
| < 90 × 109/L | 31 | 45 | 81 |
| ≥ 90 × 109/L | 30 | 37 | 70 |
| CD38 expression (%) | |||
| < 30 | 48 | 44 | 77 |
| ≥ 30 | 12 | 33 | 67 |
| IGHV mutation status | |||
| Mutated | 28 | 46 | 75 |
| Unmutated‡ | 25 | 36 | 84 |
| FISH genomic abnormalitym§ | |||
| 17p del | 8 | 13 | 63 |
| 11q del | 10 | 40 | 70 |
| Trisomy 12q | 8 | 63 | 63 |
| No abnormality | 7 | 71 | 100 |
| 13q del (sole) | 25 | 32 | 80 |
| O-FC courses received, no. | |||
| 6 | 39 | 56‖ | 92‖ |
| 4-5 | 9 | 33 | 78 |
| 1-3 | 13 | 0 | 23 |
| Characteristic . | n* . | CR rate, % . | OR rate, % . |
|---|---|---|---|
| All patients | 61 | 41 | 75 |
| Sex | |||
| Male | 43 | 35 | 70 |
| Female | 18 | 56 | 89 |
| Age, y | |||
| < 65 | 50 | 44 | 76 |
| ≥ 65 | 11 | 27 | 73 |
| ECOG performance status | |||
| 0 | 34 | 47 | 82 |
| 1-2 | 27 | 33 | 67 |
| Palpable lymph nodes | |||
| ≤ 5 cm | 51 | 39 | 78 |
| > 5 cm | 10 | 50 | 60 |
| Rai stage | |||
| 0-II | 33 | 36 | 73 |
| III-IV | 28 | 46 | 79 |
| Binet stage | |||
| A | 8 | 38 | 75 |
| B | 33 | 42 | 79 |
| C | 20 | 40 | 70 |
| β-2M† | |||
| < 4 mg/L | 32 | 53 | 84 |
| ≥ 4 mg/L | 28 | 29 | 68 |
| Lactate dehydrogenase† | |||
| < 228 IU/L | 30 | 40 | 77 |
| ≥ 228 IU/L | 31 | 42 | 74 |
| Thymidine kinase† | |||
| < 29 IU/L | 29 | 45 | 76 |
| ≥ 29 IU/L | 30 | 40 | 80 |
| ALC† | |||
| < 90 × 109/L | 31 | 45 | 81 |
| ≥ 90 × 109/L | 30 | 37 | 70 |
| CD38 expression (%) | |||
| < 30 | 48 | 44 | 77 |
| ≥ 30 | 12 | 33 | 67 |
| IGHV mutation status | |||
| Mutated | 28 | 46 | 75 |
| Unmutated‡ | 25 | 36 | 84 |
| FISH genomic abnormalitym§ | |||
| 17p del | 8 | 13 | 63 |
| 11q del | 10 | 40 | 70 |
| Trisomy 12q | 8 | 63 | 63 |
| No abnormality | 7 | 71 | 100 |
| 13q del (sole) | 25 | 32 | 80 |
| O-FC courses received, no. | |||
| 6 | 39 | 56‖ | 92‖ |
| 4-5 | 9 | 33 | 78 |
| 1-3 | 13 | 0 | 23 |
ALC indicates absolute lymphocyte count; and FISH, fluorescence in situ hybridization.
Patient numbers do not add up to N = 61 for some of the categories due to missing assessments.
Cutoff values were based on median levels at baseline.
Defined as ≥ 98% homology to closest germline sequence.
Based on Dohner hierarchy.24
P < .05, Fisher's exact test.